TP-13 is an
anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to
benzodiazepine drugs, but is structurally distinct and so is classed as a
nonbenzodiazepine anxiolytic. It is a subtype-selective
partial agonist at
GABAA receptors, binding selectively to GABAA receptor complexes bearing α2 and α3 subunits.[1] It has modest
anticonvulsant activity although less than that of
diazepam,[2] and its main effect is likely to be selective
anxiolytic action, as seen with other related α2/3-preferring agonists such as
L-838,417.
References
^McCabe C, Shaw D, Atack JR, Street LJ, Wafford KA, Dawson GR, et al. (February 2004). "Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour". Neuropharmacology. 46 (2): 171–8.
doi:
10.1016/j.neuropharm.2003.09.004.
PMID14680756.
S2CID38218522.
^Fradley RL, Guscott MR, Bull S, Hallett DJ, Goodacre SC, Wafford KA, et al. (June 2007). "Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands". Journal of Psychopharmacology. 21 (4): 384–91.
doi:
10.1177/0269881106067255.
PMID17092983.
S2CID34355306.